ArticleResearch square2025
Improving Type 2 Diabetes Prediction: Comparative Evaluation of Machine Learning Classifiers Using Balanced Data from the AWI-Gen Cohort.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Background: Type 2 diabetes mellitus (T2DM) is an escalating public health concern across Africa, but regionally tailored predictive models are scarce. Advances in machine learning (ML) offer potential for early identification, though previous research has been constrained by methodological issues such as data leakage, class imbalance, and overfitting, limiting clinical deployment, especially in digital health contexts. Methods: This study analysed data from 2,010 participants in the H3Africa AWI-Gen cohort in northern Ghana to develop and evaluate ML-based prediction models tailored to African settings. Rigorous preprocessing steps, including handling class imbalance with SMOTE and excluding diagnostic biomarkers prone to target leakage, were applied. Eight ML classifiers underwent robust Bayesian hyperparameter optimisation. Model performance was assessed via stratified 5-fold cross-validation and confirmed through extensive sensitivity and calibration analyses. Results: The optimised XGBoost model yielded an AUC of 0.845 (95% CI: 0.812-0.878) and a sensitivity of 78.2% on unseen data. Including glucose as a predictor increased performance by 11.5%, underscoring the necessity of its exclusion to avoid biased evaluation. Models using only anthropometric and lifestyle variables (AUC = 0.783) demonstrated robust predictive capacity, with waist circumference, physical activity, and BMI standing out as the most stable predictors across analyses. Conclusion: Our findings demonstrate that ML models constructed from routinely collected clinical and lifestyle data can attain clinically meaningful diabetes prediction suitable for digital health applications in low-resource African contexts. This study addresses prior methodological gaps and offers a data-driven framework that is both robust and clinically plausible for early T2DM detection, with potential implications for public health policy and digital screening programmes in similar populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.